Association of genetic polymorphisms with histological grading of necroinflammation, staging of fibrosis, and liver function in mexicans with chronic hepatitis c virus infection

Journal of Investigative Medicine

Volumn 61, Issue 7, 2013, Pages 1088-1096

  Saínchez Parada, María Guadalupe ^a   Alvarez Rodríguez, Bertha Adriana ^a   Goímez Meda, Belinda Claudia ^a   Troyo Sanromán, Rogelio ^b   Sánchez Orozco, Laura Verónica ^a   Zamora Perez, Ana Lourdes ^b   Landeros, Martha Silvia Lucano ^a   Armendáriz Borunda, Juan ^a,c  

^a Human Genetics Program   (Mexico)

^b UNIVERSITY OF GUADALAJARA   (Mexico)

^c INNOVARE   (Mexico)

Author keywords

Angiotensinogen; Fibrosis; Matrix metalloproteinases; PAI 1; TGFB1

Indexed keywords

INTERSTITIAL COLLAGENASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; STROMELYSIN; TRANSFORMING GROWTH FACTOR BETA1; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; LIVER FUNCTION; MALE; PROTHROMBIN TIME; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; STAGING; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLELE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COLOR DOPPLER FLOWMETRY; CONTROLLED STUDY; GENE; GENETIC SCREENING; HEPATITIS C VIRUS; HISTOLOGY; INFLAMMATION; LIVER BIOPSY; MIDDLE AGED; PAI 1 GENE; POLYMERASE CHAIN REACTION;

HEPATITIS C VIRUS;

AGED; ALLELES; FEMALE; GENETIC ASSOCIATION STUDIES; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; MATRIX METALLOPROTEINASE 3; MEXICO; MIDDLE AGED; NECROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; SERUM ALBUMIN; SERUM GLOBULINS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84888256619     PISSN: 10815589     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/jim.0b013e3182a32e24     Document Type: Article

References (43)

1. Powell EE, Edwards CJ, Hay JL, et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology. 2000;31(4):828Y833.
2. Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: A critical appraisal. Hepatology. 2003;37:493Y503.
3. Dixon JB, Bhathal PS, Jonsson JR, et al. Pro fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. J Hepatol. 2003;39:967Y971.
4. Richardson MM, Powell EE, Barrie HD, et al. A combination of genetic polymorphisms increases the risk of progressive disease in chronic hepatitis C. J Med Genet. 2005;42:e45.
5. Duvnjak M, Barsic N, Tomasic V, et al. Genetic polymorphisms in non-alcoholic fatty liver disease: clues to pathogenesis and disease progression. World J Gastroenterol. 2009;15:6023Y6027.
6. Hotta K, Yoneda M, Hyogo H, et al. Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of non-alcoholic fatty liver disease. BMC Med Genet. 2010; 11:172.
7. Iwata R, Baur K, Stieger B, et al. Swiss Hepatitis C Cohort Study Group. A common polymorphism in the ABCBII gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease. Clin Sci (Lond). 2011;120:287Y296.
8. Curto TM, Lagier RJ, Lok AS, et al. Predicting cirrhosis and clinical outcomes in patients with advanced chronic C with a panel of genetic markers (CRS7). Pharmacogenet Genomics. 2011;21: 851Y860.
9. Bouzgarrou N, Hassen E, Bahri O, et al. Combined effect of pro and anti-inflammatory cytokine gene polymorphisms on susceptibility to liver cirrhosis in Tunisian HCV-infected patients. Hepatol Int. 2011;5:681Y687.
10. Borde WA, Noble NA. Mechanisms of disease: transforming growth factor-beta in tissue fibrosis. N Engl J Med. 1994;331:1286Y1292.
11. Branton MH, Kopp JB. TGF-beta and fibrosis. Microbes Inf. 1999;1:1349Y1365.
12. Gálvez-Gastélum FJ, Sandoval-Rodŕguez AS, Armendáriz-Borunda J. El factor de crecimiento transformante A como blanco terapéutico. Salud Pública Méx. 2004;46:341Y350.
13. Derynck R, Rhee L, Chen EY, et al. Intron-exon structure of the human transforming growth factor beta precursor gene. Nucleic Acid Res. 1987;15:3188Y3189.
14. Tag CG, Mengsteab S, Hellerbrand C, et al. Analysis of the transforming growth factor-A1 (TGF-A1) codon 25 gene polymorphism by LightCycler-analysis in patients with chronic hepatitis C infection. Cytokine. 2003;24:173Y181.
15. Gewalting J, Mangasser K, Gartung C, et al. Association of polymorphisms of the transforming growth factor-beta 1 gene with the rate of progression of HCV-induced liver fibrosis. Clin Chim Acta. 2002;316:83Y94.
16. Xaubet A, Marin A, Lario S, et al. Transforming growth factor b1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168:431Y435.
17. Bataller R, Gines P, Nicolas JM, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology. 2000;118:1149Y1156.
18. Bataller R, Sancho-Bru P, Gines P, et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology. 2003;125:117Y125.
19. Inoue I, Nakajima T, Williams CS, et al. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and effects basal transcription in vitro. J Clin Invest. 1997;99:1786Y1797.
20. Friedman SL. Hepatic fibrosis. In: Schiff ER, ed. Schiffs Diseases of the Liver, 9th ed. Philadelphia, PA: Lippincott Williams and Wilkins, 2003;409Y427.
21. Nagase H, Woessner JF. Matrix metalloproteinase. J Biol Chem. 1999;274:21491Y21494.
22. Rutter JL, Mitchell TI, Bauttice G, et al. Single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates and Ets binding site and augments transcription. Cancer Res. 1998;58:5321Y5355.
23. Ye S, Eriksson P, Hamsten A, et al. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem. 1996;271:13050Y13060.
24. Ridker PM, Gaboury CL, Conclin PR, et al. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the rennin- angiotensin system and fibrinolytic function. Circulation. 1993;87:1969Y1973.
25. Mansfield MW, Stickland MH, Grant PJ, et al. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non insulin-dependent diabetes mellitus. Thromb Haemost. 1995;74:842Y847.
26. Margaglione M, Cappucci G, d'Addedda M, et al. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants arteriosclerosis. Thromb Vasc Biol. 1998;18:562Y567.
27. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22: 696Y699.
28. Miller S, Dykes D, Polesky H. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16:1215.
29. Armendáriz-Borunda J, Rincón AR, Munoz-Valle JF, et al. Fibrogenic polymorphisms (TGF-beta, PAI-1, AT) in Mexican patients with established liver fibrosis. Potential correlation with pirfenidone treatment. J Investig Med. 2008;56:944Y953.
30. Wang H, Mengsteab S, Tag C, et al. Transforming growth factor-A1 gene polymorphisms are associated with progression of liver fibrosis in Caucasians with chronic hepatitis C infection. World J Gastroenterol. 2005;11(13): 1929Y1936.
31. Hahn AW, Resink TJ, Bernhardt J, et al. Stimulation of autocrine platelet derived growth factor AA-homodimer and transforming growth factor beta in vascular smooth muscle cells. Biochem Biophys Res Commun. 1991;178:1451Y1458.
32. Eurich D, Bahra M, Boas S, et al. Transforming growth factor A1 polymorphisms and progression of graft fibrosis after liver transplantation for hepatitis C virus induced liver disease. Liver Transpl. 2011;17:279Y288.
33. Awad MR, El-Gamel A, Hasleton P, et al. Genotypic variation in the transforming growth factor A1 gene: association with transforming growth factor A1 production, fibrotic lung diseases, and graft fibrosis after lung transplantation. Transplantation. 1998;66:1014Y1020.
34. Lacha J, Hubacek JA, Potmesil P, et al. TGF- beta I gene polymorphism in heart transplant recipientsVeffect on renal function. Ann Transplant. 2001;6:39Y43.
35. Veras ER, Cardenas L, González I, et al. Controlled clinical trial with pirfenidone in the treatment of breast capsular contracture. Ann Plast Surg. 2013;70(1):16Y22.
36. Sánchez R, Galaviz C, Sierra JA, et al. Polimorfismo 677CT del gen de la metilentetradihidrofolato reductasa y cardiopat́as congenitas aisladas en población Mexicana. Rev Esp Cardiol. 2012;65(2):158Y163.
37. Shin HP, Lee JI, Jung JH, et al. Matrix metalloproteinase (MMP)-3 polymorphism in patients with HBV related chronic liver disease. Dig Dis Sci. 2008;53:823Y829.
38. Okamoto K, Mimura K, Murawaki Y, et al. Association of functional gene polymorphisms of matrix metalloproteinase (MMP)-1, MMP-3 and MMP-9 with the progression of chronic liver disease. J Gastroenterol Hepatol. 2005;20:1102Y1108.
39. La Spada E, Soresi M, Giannitrapani L, et al. Long-term follow-up of hepatitis C virus-ositive patients with persistently normal serum transaminases. Ann Hepatol. 2013;12(1): 36Y43.
40. Puoti C, Guarisco R, Spilabotti L, et al. Should we treat HCV carriers with normal ALT levels The '5Ws' dilemma. J Viral Hepat. 2012;19: 229Y235.
41. Fabris C, Falleti E, Cussigh A, et al. The interleukin 28B rs12979860 C/T polymorphism and serum cholesterol as predictors of fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases. J Med Virol. 2012;84: 747Y755.
42. Karp WB, Subramanyam SB, Ho CK, et al. Drugs affecting bilirubin uptake by human erythrocyte ghosts. Am J Med Sci. 1985;289(6):236Y239.
43. Fevery J. Bilirubin in clinical practice: A review. Liver Int. 2008;28(5):592Y605.